Trial Profile
Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms REALME
- 12 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
- 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.
- 30 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Mar 2016, according to ClinicalTrials.gov record.